- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02574507
Behavioral Weight and Symptom Management for Breast Cancer Survivors and Partners
May 5, 2020 updated by: Duke University
The objective of the study is to develop and test the feasibility, acceptability, and initial efficacy of a novel couples-based behavioral weight and symptom management intervention for obese breast cancer survivors and their partners.
The proposed project consists of two phases.
Phase I will include intervention development and refinement.
Intervention development will be guided by the research team's prior work, the interdependence model of communal coping and behavior change, and information obtained from couples participating in focus groups.
The intervention protocol will then be tested with 5 couples to assist with refinement of intervention content.
During phase II, the feasibility, acceptability and initial efficacy of the intervention will be examined.
Obese breast cancer survivors in the three years following treatment and their overweight or obese partners will receive 6 weekly and 6 biweekly sessions for a total of 12 sessions spaced across approximately 5 months.
The intervention will be provided in a couples-based format where each couple will meet separately with the therapist.
Couples will be assessed at pre-, post-, and 3-months post-treatment.
Study outcomes will be weight, symptoms (i.e., pain, fatigue, distress), eating behavior, and physical activity.
Exploratory outcomes examine biomarkers (i.e., insulin, IL-6, IL-8, TNF-alpha, adiponectin) associated with health outcomes for cancer survivors and their partners.
It is hypothesized that the intervention will be feasible (i.e., completed sessions), and participants will find the intervention acceptable as assessed by a measure of treatment acceptability.
It is also hypothesized that participants will evidence decreased weight and improvements in symptoms (i.e., pain, fatigue, distress), eating behavior, and physical activity, and their change in weight will covary with change in symptoms, eating behavior, and daily physical activity.
Finally, it is hypothesized that participants with greater weight loss will evidence improved functioning in insulin, IL-6, IL-8, TNF-α, adiponectin, and heart rate.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
52
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke Cancer Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Phase I: Intervention Development and Refinement:
Inclusion Criteria:
Patients:
- Female,
- obese (BMI >30)
- partnered
- diagnosis of non-metastatic breast cancer (stages I-III)
- completed adjuvant chemotherapy and/or radiation treatment in the last 5 years
- healthy enough to participate in a home-based walking program (if participating in intervention refinement),
- able to speak English
- able and willing to give informed consent.
Partners:
- Overweight/obese (BMI >25)
- cohabiting partner of a woman with non-metastatic breast cancer completing adjuvant chemotherapy and/or radiation in the last 5 years
- healthy enough to participate in a home-based walking program (if participating in intervention refinement)
- able to speak English
- able and willing to give informed consent.
Exclusion Criteria: for both patients and partners
- male breast cancer survivors
- non-ambulatory
- unable to provide informed consent
- have a major mental illness (i.e., schizophrenia);
- have a mental illness that is not being treated/controlled (i.e., bipolar disorder)
- reside > 100 miles from the research site.
Phase II: Feasibility, Acceptability, and Efficacy of the Intervention
Inclusion Criteria:
Patients:
- Female, obese (BMI >30)
- partnered
- diagnosis of non-metastatic breast cancer (stages I-III)
- completed adjuvant chemotherapy and/or radiation treatment in the last 3 years
- healthy enough to participate in a home-based walking program
- able to speak English
- able and willing to give informed consent.
Partners:
- Overweight/obese (BMI >25)
- cohabiting partner of a woman with non-metastatic breast cancer completing adjuvant chemotherapy and/or radiation in the three years
- healthy enough to participate in a home-based walking program
- able to speak English
- able and willing to give informed consent.
Exclusion Criteria: for both patients and partners
- male breast cancer survivors
- non-ambulatory
- unable to provide informed consent
- have a major mental illness (i.e., schizophrenia)
- have a mental illness that is not being treated/controlled (i.e., bipolar disorder)
- reside > 100 miles from the research site.
- Pregnant women will also be excluded from the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Couples-Based Behavioral Weight and Symptom Management
Participants will receive 12 session (6 weekly and 6 biweekly) of a behavioral weight and symptom management intervention.
|
Investigators anticipate that the intervention developed in phase I will consist of a total of 12 sessions 90 minutes in length (18 therapy hours) spaced across approximately 5 months.
Sessions are spaced to provide participants sufficient time to complete home practice exercises and adequately examine change in weight and maintenance of weight loss.
Sessions will be conducted individually for each day.
The first 6 sessions will occur weekly and the final 6 sessions will occur biweekly.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Weight
Time Frame: baseline, week 1, week 2, week 3, week 4, week 5, week 6, week 8, week 10, week 12, week 14, week 16, week 18, post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks)
|
Participants will be weighed at each assessment and each session.
|
baseline, week 1, week 2, week 3, week 4, week 5, week 6, week 8, week 10, week 12, week 14, week 16, week 18, post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks)
|
Change in steps per day
Time Frame: Through study completion (an average of 31 weeks)
|
Participants will wear wireless activity trackers (Fitbits) to measure daily activity (e.g., steps taken).
Participants will be provided with the activity trackers by study staff and begin to use the trackers following the pre-treatment assessment.
Participants will continue to use the trackers throughout treatment.
Participants will return the Fitbits to the study staff upon completion of the study.
|
Through study completion (an average of 31 weeks)
|
Change in 6 minute walk ability score
Time Frame: baseline, post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks)
|
The 6-minute walk test is a self-paced, timed test of the total distance in meters that a patient is able to walk over a six-minute period and assesses the ability to exert effort during activity.
|
baseline, post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks)
|
Change in 6 minute walk pain score
Time Frame: baseline, post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks)
|
The degree of pain experienced during the 6-minute walk test will also be assessed.
|
baseline, post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks)
|
Change in Stanford Leisure-Time Activity Categorical Item (L-Cat)
Time Frame: baseline , post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks)
|
The L-Cat is a measure of physical activity.
Individuals identify which descriptive category best describes their level of activity during leisure time in the last month.
Descriptive categories range from inactive to very active.
|
baseline , post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks)
|
Change in Eating Behavior
Time Frame: baseline , post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks)
|
Participants will also be asked to complete the Dietary Instrument for Nutrition Education (DINE).
The DINE is a brief assessment of the amount of fat and dietary fiber in an individual's usual diet.
Participants are provided with a list of food items and asked about the frequency with which they have eaten the items per week when considering the last month.
|
baseline , post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks)
|
Change in The Brief Pain Inventory (BPI)
Time Frame: baseline , post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks)
|
The BPI is a 9-item self-report measure assessing pain severity.
Participants rate their pain on a scale from 0 to 10 where 0 represents "no pain" and 10 represents "pain as bad as you can imagine."
Participants also rate their level of interference from pain.
|
baseline , post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks)
|
Change in Promis Fatigue Scale
Time Frame: pre-treatment, post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks)
|
The Promis Fatigue Scale is a 6-item self-report measure of fatigue in the last week
|
pre-treatment, post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks)
|
Change in Profile of Mood States (POMS)
Time Frame: baseline , post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks)
|
The POMS will be used to assess psychological distress.
Each item is rated on a scale from 0 (not at all) to 4 (extremely) as being self-descriptive for the last seven days.
|
baseline , post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks)
|
Change in Physical Activity based on the International Physical Activity Questionnaire
Time Frame: pre-treatment, post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks)
|
Participants will also complete the International Physical Activity Questionnaire (IPAQ).
This seven-item questionnaire assesses the amount of time participants have spent doing moderate and vigorous physical activities in the last seven days.
|
pre-treatment, post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks)
|
Change in eating behavior using the Three Factor Eating Questionnaire
Time Frame: pre-treatment, post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks)
|
Eating behaviors will be assessed using the Three Factor Eating Questionnaire (TFEQ).
The 21-item short-form will be used for the present study.
The TFEQ measures three domains of eating behavior: 1) cognitive restraint, 2) uncontrolled eating, and 3) emotional eating.
|
pre-treatment, post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Fasting insulin
Time Frame: baseline and 3 months post-treatment (approximately 30-32 weeks)
|
Fasting insulin will be examined by taking a sample of peripheral blood from participants at the baseline and post-treatment assessments.
|
baseline and 3 months post-treatment (approximately 30-32 weeks)
|
Change in IL-6
Time Frame: baseline and 3 months post-treatment (approximately 30-32 weeks)
|
The pro-inflammatory cytokine IL-6 will be examined by taking a sample of peripheral blood from participants at the baseline and post-treatment assessments.
|
baseline and 3 months post-treatment (approximately 30-32 weeks)
|
Change in IL-8
Time Frame: baseline and 3 months post-treatment (approximately 30-32 weeks)
|
The pro-inflammatory cytokine IL-8 will be examined by taking a sample of peripheral blood from participants at the baseline and post-treatment assessments.
|
baseline and 3 months post-treatment (approximately 30-32 weeks)
|
Change in TNF-alpha
Time Frame: baseline and 3 months post-treatment (approximately 30-32 weeks)
|
The pro-inflammatory cytokine TNF-alpha will be examined by taking a sample of peripheral blood from participants at the baseline and post-treatment assessments.
|
baseline and 3 months post-treatment (approximately 30-32 weeks)
|
Change in Adiponectin
Time Frame: baseline and 3 months post-treatment (approximately 30-32 weeks)
|
The anti-inflammatory cytokine adiponectin will be examined by taking a sample of peripheral blood from participants at the baseline and post-treatment assessments.
|
baseline and 3 months post-treatment (approximately 30-32 weeks)
|
Change in Heart Rate
Time Frame: Through study completion (an average of 31 weeks)
|
Heart rate will be assessed via the wireless activity trackers (Fitbit) worn by participants throughout the study.
|
Through study completion (an average of 31 weeks)
|
Treatment Acceptability Questionnaire (TAQ)
Time Frame: post-treatment (approximately 30-32 weeks)
|
The Treatment Acceptability Questionnaire (TAQ) is a six-item scale assessing whether participants view an intervention as acceptable, ethical, and effective.
Items are rated on a 7-point Likert scale (e.g., 1 "very unacceptable" to 7 "very acceptable).
|
post-treatment (approximately 30-32 weeks)
|
Change in Session attendance rate
Time Frame: week 1, week 2, week 3, week 4, week 5, week 6, week 8, week 10, week 12, week 14, week 16, week 18
|
Treatment feasibility will be assessed by measuring the session attendance rate for each participant and each day.
|
week 1, week 2, week 3, week 4, week 5, week 6, week 8, week 10, week 12, week 14, week 16, week 18
|
Change in Use of intervention strategies
Time Frame: week 1, week 2, week 3, week 4, week 5, week 6, week 8, week 10, week 12, week 14, week 16, week 18
|
Participants' use of intervention strategies will be assessed using a measure developed for components of the present study.
Participants will be asked about how frequently treatment strategies discussed in session have been used outside of session in the past week or past month depending on the timing of the questionnaire.
A scale ranging from 0 "not at all" to 5 "2 or more times a day" will be used.
|
week 1, week 2, week 3, week 4, week 5, week 6, week 8, week 10, week 12, week 14, week 16, week 18
|
Change in partner support for eating and exercise
Time Frame: pre-treatment, post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks)
|
Partner support for eating and exercise will be assessed using a modified version of the Social Support for Diet and Exercise questionnaires.
Participants will be asked to provide information about the amount of encouragement and discouragement they have received from their partner over the last three months regarding healthy eating and exercise.
Items are rated on a 5 point scale from 1 "none" to 5 "very often."
|
pre-treatment, post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks)
|
Change in Self-Efficacy for Weight
Time Frame: pre-treatment, post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks); at each intervention session (week 1, week 2, week 3, week 4, week 5, week 6, week 8, week 10, week 12, week 14, week 16, week 18)
|
The Weight Efficacy Lifestyle Questionnaire is an 8-item measure of eating self-efficacy.
Participants are asked to provide information about how certain they are that they can resist overeating in difficult situation (e.g., over the weekend, when tired, etc.).
Response choices range from 0= "not at all confident" to 10= "very confident."
|
pre-treatment, post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks); at each intervention session (week 1, week 2, week 3, week 4, week 5, week 6, week 8, week 10, week 12, week 14, week 16, week 18)
|
Change in self-efficacy for managing chronic disease
Time Frame: pre-treatment, post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks); at each intervention session (week 1, week 2, week 3, week 4, week 5, week 6, week 8, week 10, week 12, week 14, week 16, week 18)
|
The Self-Efficacy for Managing Chronic Disease Scale is a 6-item scale that asks participants to rate their confidence in doing certain activities (e.g., keep emotional distress from interfering with the things you want to do) on a scale from 1= "not at all confident" to 10= "totally confident."
The wording of items was slightly altered to better match the sample intended for the present study.
|
pre-treatment, post-treatment (approximately 18-20 weeks), 3 months post-treatment (approximately 30-32 weeks); at each intervention session (week 1, week 2, week 3, week 4, week 5, week 6, week 8, week 10, week 12, week 14, week 16, week 18)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Caroline S Dorfman, PhD, Duke University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2015
Primary Completion (Actual)
December 1, 2018
Study Completion (Actual)
December 1, 2018
Study Registration Dates
First Submitted
October 5, 2015
First Submitted That Met QC Criteria
October 9, 2015
First Posted (Estimate)
October 14, 2015
Study Record Updates
Last Update Posted (Actual)
May 6, 2020
Last Update Submitted That Met QC Criteria
May 5, 2020
Last Verified
May 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00063328
- 1F32CA200091-01 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Couples-Based Behavioral Weight and Symptom Management
-
Hannover Medical SchoolGerman Federal Ministry of Education and ResearchUnknownMedication Adherence | Rejection | Self ManagementGermany
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of MarylandCompleted
-
University of British ColumbiaCompleted
-
Stony Brook UniversityCompletedChronic Fatigue Syndrome | Medically Unexplained Chronic FatigueUnited States
-
Duke UniversityPalliative Care Research Cooperative GroupCompletedAdvanced CancerUnited States
-
University of KansasNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Fox Chase Cancer CenterActive, not recruiting
-
Duke UniversityNational Cancer Institute (NCI)Active, not recruitingMelanoma | Pain | Cancer | Breast Cancer | Fatigue | Psychological Distress | Germ Cell Tumor | Young Adult | Hematologic Cancer | Endocrine CancerUnited States
-
University Hospital FreiburgGerman Medical AssociationCompletedDepressive DisorderGermany